Seoul, South Korea – On October 10, Shanghai MicroPort Medical (Group) Co ("MicroPort®") announced that its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") obtained the Korea Good Manufacturing Practice ("KGMP") from the Ministry of Food and Drug Safety ("MFDS") of South Korea.
According to statistics, South Korea ranks No.3 in Asia in the size of its medical device market, following Japan and China. In spite of the huge market, it is not easy for foreign companies to register medical devices in the South Korea market since they have to comply with strict quality system regulations required by the South Korean government. In November 2014, MicroPort® received the on-site inspection by the MFDS for its JIVE balloon product before its market launch in South Korea, and successfully passed the auditing to obtain the KGMP certification in December 2014.
As Firehawk® was granted the KGMP certification, it once again proved that MicroPort® quality system complies with the KGMP quality system regulations, and meanwhile it paves the way for Firehawk® to receive the regulatory approval in the South Korea market.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.